Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of CF101 to Treat Keratoconjunctivitis Sicca

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female, 18 years of age and over;~* Have a diagnosis of moderate-to-severe KCS as defined by: (1) Schirmer Test (ST) (without anesthesia) \< 7 mm/5 min in either eye; AND (2) Positive FS, defined as a corneal punctate fluorescein staining score of ≥1 in either eye, where 0 = none and 3= severe; AND (3) At least 1 of the following ocular symptoms scored at ≥2, where 0 = none and 4 = very severe/interferes with normal activities: photophobia, blurred vision, foreign body sensation, soreness or pain, itching, burning, dryness;~* Willing to use no topical ocular treatments except for the unpreserved artificial tears;~* Doses of unpreserved artificial tears have been stable for \>2 weeks prior to Screening Visit;~* Females of child-bearing potential must have a negative urine pregnancy test at screening and throughout the study, to be eligible for, and continue participation in, the study;~* Females of child-bearing potential must be willing to use 2 methods of contraception deemed adequate by the Investigator (for example oral contraceptive pills plus a barrier method) to be eligible for, and continue participation in, the study;~* Ability to complete the study in compliance with the protocol; and~* Ability to understand and provide written informed consent.~Exclusion Criteria:~* Has Sjögren's Syndrome with significant systemic non-exocrine gland involvement;~* Has Stevens-Johnson Syndrome;~* If KCS is due to rheumatoid arthritis or other autoimmune diseases, patient may not be receiving disease-modifying drugs, including methotrexate and biological agents;~* Use of systemic immunosuppressive drugs;~* Use of oral corticosteroids \>10 mg prednisone, or equivalent, per day;~* Use of topical steroids within 2 weeks prior to the Screening Visit and for the duration of the study;~* Receipt of topical cyclosporine eye drops within 3 months prior to the Screening Visit and for the duration of the trial;~* Presence of chronic ocular disease other than KCS requiring topical treatment;~* Presence of post-burn ocular injury;~* Ocular herpes simplex virus infection;~* Concomitant use of contact lenses;~* Persistent intraocular inflammation or infection;~* Active blepharitis;~* Recent surgical occlusion of the lacrimal puncta;~* Subepithelial corneal scarring;~* Anesthetic or neurotrophic corneas;~* Hemoglobin level \<9.0 gm/L;~* Platelet count \<125,000/mm\^3;~* White blood cell count \<3500/mm\^3;~* Serum creatinine level outside the laboratory's normal limits;~* Liver aminotransferase levels greater than 2 times the laboratory's upper limit of normal;~* Pregnancy, planned pregnancy, lactation, or inadequate contraception as judged by the Investigator;~* History of malignancy within the past 5 years (excluding basal cell carcinoma of the skin);~* Significant acute or chronic medical, ophthalmic, or psychiatric illness that, in the judgment of the Investigator, could compromise patient safety, limit the patient's ability to complete the study, and/or compromise the objectives of the study;~* Participation in another investigational drug or vaccine trial concurrently or within 30 days; or~* Other conditions which would confound the study evaluations or endanger the safety of the patient.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CF101 1mg (Type: EXPERIMENTAL): CF101 1 mg given orally every 12 hours for 12 weeks
- Placebo (Type: PLACEBO_COMPARATOR): Placebo given orally every 12 hours for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).